Skip to content

Multimodal psychodynamic group therapy in routine day-clinic and inpatient care: Naturalistic study on effectiveness and adverse events

Multimodal psychodynamic group therapy in routine day-clinic and inpatient care: Naturalistic study on effectiveness and adverse events

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00035824
Enrollment
150
Registered
2025-01-21
Start date
2025-01-21
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

All ICD-10 or ICD-11 F-diagnoses treated in the study center.

Interventions

Group 1: 9-week Standard Treatment of 4 Inpatient Therapy Groups of the Psychosomatic Study Clinic: The multimodal treatment, primarily psychodynamically oriented, is carried out mainly in a group set

Sponsors

Institut für Psychosoziale Medizin, Psychotherapie und Psychoonkologie, Universitätsklinikum Jena
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: none

Exclusion criteria

Exclusion criteria: Treatment duration < 2 weeks

Design outcomes

Primary

MeasureTime frame
Time Points: 1. Start of treatment (pre) 2. Continuously/weekly during treatment 3. After approximately the first third/half of treatment (mid) 4. End of treatment (post) 5. 6 months after the end of treatment (fu1) 6. 12 months after the end of treatment (fu2) Primary Endpoints a) Subjective Health Status/Symptoms: - Gesundheitsinventar Psychosomatik (gi-ps) - pre, post, fu1, fu2 - Depression: Patient Health Questionnaire-9 (PHQ-9) - pre, post, fu1, fu2 - Subjective Symptoms: Clinic-specific Symptom Questionnaire (BFB-C) - pre, post, fu1, fu2 - Self-assessment of current emotional and psychological state: German version of the Emotional and Psychological Outcome-1 Item (EPO-1) - pre, weekly, post, fu1, fu2 b) Level of Structural Integration:Strukturfragebogen Kurzform (OPD-SFK) - pre, post, fu1, fu2 c) Negative Effects: - Self- (patient version) and external (therapist version) assessment questionnaires on negative effects of the treatment (including characteristics such as extent, duration, and cause): Modified versions of the Negative Effects Questionnaire – German short version (NEQ-20+P - mid, post, fu1, fu2, NEQ-20+Th - post) - Subjective burden of therapy (custom item created for the study with a 5-point Likert scale) - weekly, post, fu1, fu2 d) Subjective Treatment Evaluation: - Weekly reports by patients on helpful and challenging aspects of the treatment (study-specific open-ended questions): weekly - Treatment evaluation (patient and therapist versions, study-specific questionnaires with Likert scales, rating of individual therapy components, and open-ended questions) - post, fu1, fu2 e) For closed therapy groups only: External assessment of personality restructuring (by therapists) - Heidelberger Umstrukturierungsskala (HUS) - mid, post

Secondary

MeasureTime frame
f) Relatives' Perspective on Therapy: - Relatives' Questionnaire (study-specific questionnaire) - fu1, fu2 - Relatives' Interview (study-specific interview) - fu1 g) Life Satisfaction: Short Scale for Measuring General Life Satisfaction (L-1), supplemented with an assessment of satisfaction in various life domains, weighted individually beforehand - pre, post, fu1, fu2 h) Backgrounds and Significance of Premature Therapy Termination: Questionnaire on Premature Therapy Termination (patient and therapist versions, study-specific questionnaires)

Countries

Germany

Contacts

Public ContactRahel Klatte

Institut für Psychosoziale Medizin, Psychotherapie und Psychoonkologie, Universitätsklinikum Jena

rahel.klatte@t-online.de+491781580382

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026